# US 2008/0305174 A1 · Polymeric nanocapsules for use in drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305174 A1
- Document ID: US20080305174A1
- Status: Published application
- Kind: A1
- Application number: 11/760,083
- Filed: 2007-06-08
- Published: 2008-12-11
- Earliest claimed: 2007-06-08
- Inventors: Robert J. Gyurik; Zhengmao Li
- Web page: https://patentgrep.com/patent/US20080305174A1

## CPC

- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/1273: Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
- A61K 38/28: Insulins
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to drug delivery formulations that utilize nanocapsules, such as nanovesicles, micelles, lamellae particles, polymersomes, dendrimers, and other nano-size particles of various other fabrications, including those that are known in the art. The invention employs diblock copolymers or single block polymers that hold, adhere to, absorb or encapsulate drug molecules, including, but not limited to, those that heretofore have not been successfully formulated for oral drug delivery, e.g., insulin. Nanocapsule holding, adherence, absorption or encapsulation of such drugs or other molecules enables their delivery via oral or mucosal means.

## Claims

### Claim 1

A composition comprising:
a diblock copolymer comprising polymer blocks A and B, wherein
A is at least a partially hydrophobic block and
B is at least a partially hydrophilic block, and
wherein A and B further comprise amino acids or derivatives of amino acids.

### Claim 2 (depends on 1)

A composition according to claim 1 wherein block A comprises an n-butyl-poly-l-lactide polymer or a derivative thereof.

### Claim 3 (depends on 1)

A composition according to claim 1 wherein block B comprises a poly-l-glutamic acid polymer or a derivative thereof.

### Claim 4 (depends on 1)

A composition according to claim 1 wherein the diblock polymer comprises poly(lactic acid)-poly(glutamic acid) or a derivative thereof.

### Claim 5 (depends on 1)

A composition according to claim 1 wherein the A block comprises a polylactide, polycaprolactide, or polyglycolide, or derivatives thereof, including such entities in either enantiomeric, racemic or other isomeric forms such as meso.

### Claim 6 (depends on 1)

A composition according to claim 1 wherein the B block comprises polyaminoacids, or derivatives thereof, with ionic nature, including polyaminoacids in enantiomeric, racemic, or other isomeric forms such as meso.

### Claim 7 (depends on 1)

A composition according to claim 1 wherein the B block comprises polyaminoacids, or derivatives thereof, with anionic nature, including polyaminoacids in enantiomeric, racemic, or other isomeric forms such as meso.

### Claim 8 (depends on 1)

A composition according to claim 1 wherein the B block comprises polyaminoacids, or derivatives thereof, with cationic nature.

### Claim 9 (depends on 1)

A composition according to claim 1 wherein the B block comprises polyglutamic or polyaspartic amino acids, or derivatives thereof, or copolymers of the two.

### Claim 10 (depends on 1)

A composition according to claim 1 wherein the B block comprises polylysine, polyarginine, polyhistidine, or derivatives thereof, or any combinations of copolymers thereof.

### Claim 11 (depends on 1)

A composition according to claim 1 wherein said diblock polymer forms nanocapsules.

### Claim 12 (depends on 11)

A composition according to claim 11 wherein the nanocapsules comprise nanoparticles.

### Claim 13 (depends on 11)

A composition according to claim 11 wherein the nanocapsules comprise micelles.

### Claim 14 (depends on 11)

A composition according to claim 11 wherein the nanocapsules are lamella shaped.

### Claim 15 (depends on 11)

A composition according to claim 11 wherein the nanocapsules comprise both micelles and lamellae shaped particles.

### Claim 16 (depends on 11)

A composition according to claim 11 wherein the nanocapsules comprise polymersomes.

### Claim 17 (depends on 11)

A composition according to claim 11 wherein the nanocapsules comprise nanovesicles.

### Claim 18 (depends on 11)

A composition according to claim 11 wherein the nanocapsules comprise dendrimers.

### Claim 19 (depends on 11)

A composition according to claim 11 wherein a drug is adhered to, or present on or in, all or part of the nanocapsules.

### Claim 20 (depends on 11)

A composition according to claim 11 wherein a drug is at least partially absorbed, or encapsulated by, all or part of the nanocapsules.

### Claim 21 (depends on 19)

A composition according to claim 19 wherein the drug is a peptide, polypeptide or protein.

### Claim 22 (depends on 19)

A composition according to claim 19 wherein the drug is a macromolecule.

### Claim 23 (depends on 19)

A composition according to claim 19 wherein the drug is insulin.

### Claim 24 (depends on 19)

A composition according to claim 19 wherein the drug is a derivative or analogue of insulin.

### Claim 25 (depends on 20)

A composition according to claim 20 wherein the drug is a peptide, polypeptide or protein.

### Claim 26 (depends on 20)

A composition according to claim 20 wherein the drug is a macromolecule.

### Claim 27 (depends on 20)

A composition according to claim 20 wherein the drug is insulin.

### Claim 28 (depends on 20)

A composition according to claim 20 wherein the drug is a derivative or analogue of insulin.

### Claim 29 (depends on 1)

A composition according to claim 1 wherein either or both of blocks A and B may vary in length between approximately 10 and 500 monomeric units.

### Claim 30 (depends on 1)

A composition according to claim 1 wherein either or both of blocks A and B may vary in length between approximately 25 and 200 monomeric units.

### Claim 31 (depends on 1)

A composition according to claim 1 wherein either or both of blocks A and B may vary in length between approximately 50 and 150 units.

### Claim 32 (depends on 1)

A composition according to claim 1 except wherein the composition comprises only the B block comprising a polyamino acid, or a derivative thereof, capable of complexing with a drug such that the B block protects the drug before being uptaken by the intestine.

### Claim 33 (depends on 1)

A composition according to claim 1 except wherein the composition comprises the B block but not the A block.

### Claim 34 (depends on 6)

A composition according to claim 6 except wherein the composition comprises the B block but not the A block.

### Claim 35 (depends on 7)

A composition according to claim 7 except wherein the composition comprises the B block but not the A block.

### Claim 36 (depends on 8)

A composition according to claim 8 except wherein the composition comprises the B block but not the A block.

### Claim 37 (depends on 9)

A composition according to claim 9 except wherein the composition comprises the B block but not the A block.

### Claim 38 (depends on 10)

A composition according to claim 10 except wherein the composition comprises the B block but not the A block.

### Claim 39 (depends on 1)

A composition according to claim 1 wherein the diblock polymer comprises a poly(lactic acid) block comprising about 150 lactic acid repeating units, and a poly(glutamic acid) block comprising about 100 glutamic acid repeating units.

### Claim 40 (depends on 1)

A nanocapsule comprising a composition according to claim 1.

### Claim 41 (depends on 40)

A nanocapsule according to claim 40 wherein the nanocapsule comprises a nanoparticle.

### Claim 42 (depends on 40)

A nanocapsule according to claim 40 wherein the nanocapsule comprises a micelle.

### Claim 43 (depends on 40)

A nanocapsule according to claim 40 wherein the nanocapsule comprises a lamella shaped structure.

### Claim 44 (depends on 40)

A nanocapsule according to claim 40 wherein the nanocapsule comprises a polymersome.

### Claim 45 (depends on 40)

A nanocapsule according to claim 40 wherein the nanocapsule comprises a nanovesicle.

### Claim 46 (depends on 40)

A nanocapsule according to claim 40 wherein the nanocapsule comprises a dendrimer.

### Claim 47

A method of making an amino acid or amino acid derivative diblock copolymer that forms nanocapsules, comprising:
polymerizing two individual amino acid or amino acid derivative polymeric blocks;
coupling the two blocks together to form a diblock polymer;
precipitating the diblock polymer after the coupling;
washing the precipitated diblock polymer;
forming a diblock polymer suspension;
sonicating the diblock polymer suspension, and
forming nanocapsules in the suspension.

### Claim 48 (depends on 47)

A method according to claim 47 wherein a drug is added to the nanocapsules.

### Claim 49 (depends on 48)

A method according to claim 48 wherein the drug is a peptide, polypeptide or protein.

### Claim 50 (depends on 48)

A method according to claim 48 wherein the drug is insulin.

### Claim 51 (depends on 48)

A method according to claim 48 wherein the drug is an insulin derivative or analogue.

### Claim 52 (depends on 23)

A method of treating a patient in need of insulin comprising administering to said patient a pharmaceutically acceptable amount of a composition of claim 23.

### Claim 53 (depends on 24)

A method of treating a patient in need of insulin comprising administering to said patient a pharmaceutically acceptable amount of a composition of claim 24.

### Claim 54 (depends on 27)

A method of treating a patient in need of insulin comprising administering to said patient a pharmaceutically acceptable amount of a composition of claim 27.

### Claim 55 (depends on 28)

A method of treating a patient in need of insulin comprising administering to said patient a pharmaceutically acceptable amount of a composition of claim 28.
